 13 significant clinical milestones achieved year-to-date, including critical positive data readout events for felzartamab TJ202MOR202, lemzoparlimab TJC4, uliledlimab TJD5, and plonmarlimab TJM2 and more milestone achievements are expected before the year-end 2021 Felzartamab TJ202MOR202 is on track for Biologic License Application BLA submission in Q4 2021 and eftansomatropin alfa TJ101 phase 3 trial on track for completion of patient enrollment and potential commercial collaboration Growing pipeline with eight highly differentiated and clinically advanced assets in phase 23, followed by next generation of immuno-oncology assets, including bi-specific antibodies in phase 1 or pre-clinical stage and novel drug candidates enabled by transformative technologies for unique drug properties, e.g. AI-guided targeting, antibody by mRNA delivery, intracellular targeting and tumor-site activation Inclusion of the MSCI China All Shares Index, preparation of potential dual listing on Chinas STAR Market, and receiving of a high rating from the MSCI ESG assessment the highest newly initiated rating among China-based biotech companies Progress in building the manufacturing and commercialization capabilities as part of Companys transformation to a global biopharma I-Mab to host conference calls and webcasts on August 31, 2021. 